Nadir CA-125 level is an independent prognostic factor in advanced epithelial ovarian cancer

Journal of Surgical Oncology

Volumn 100, Issue 3, 2009, Pages 244-247

  Kang, Sokbom ^a   Seo, Sang Soo ^a   Park, Sang Yoon ^a  

^a National Cancer Center   (South Korea)

Author keywords

CA 125; Cytoreductive surgery; Ovarian cancer; Prognostic factor; Progression free survival

Indexed keywords

CA 125 ANTIGEN; CARBOPLATIN; PACLITAXEL; TUMOR MARKER;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER REGRESSION; CANCER SURVIVAL; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; BLOOD; DISEASE FREE SURVIVAL; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; OVARY TUMOR; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY;

ADULT; AGED; CA-125 ANTIGEN; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MIDDLE AGED; MULTIVARIATE ANALYSIS; OVARIAN NEOPLASMS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 70249090419     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.21258     Document Type: Article

References (12)

1. Jemal A, Murray T, Ward E, et al.: Cancer statistics, 2005. CA Cancer J Clin 2005;55:10-30.
2. Ozols RF, Bundy BN, Greer BE, et al.: Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: A Gynecologic Oncology Group study. J Clin Oncol 2003;21:3194-3200. (Pubitemid 46606249)
3. Armstrong DK, Brady MF: Intraperitoneal therapy for ovarian cancer: A treatment ready for prime time. J Clin Oncol 2006;24:4531-4533. (Pubitemid 46630946)
4. Markman M, Liu PY, Wilczynski S, et al.: Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: A Southwest Oncology Group and Gynecologic Oncology Group trial. J Clin Oncol 2003;21:2460-2465. (Pubitemid 46606325)
5. De Placido S, Scambia G, Di Vagno G, et al.: Topotecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) randomized study. J Clin Oncol 2004;22:2635-2642. (Pubitemid 41103751)
6. Crawford SM, Peace J: Does the nadir CA-125 concentration predict a long-term outcome after chemotherapy for carcinoma of the ovary? Ann Oncol 2005;16:47-50.
7. Pignata S, Perrone F, Di Maio M, et al.: In Reply: J Clin Oncol 2005;23:2436-2437.
8. Markman M, Liu PY, Rothenberg ML, et al.: Pretreatment CA-125 and risk of relapse in advanced ovarian cancer. J Clin Oncol 2006;24:1454-1458. (Pubitemid 46622013)
9. Juretzka MM, Barakat RR, Chi DS, et al.: CA-125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy. Gynecol Oncol 2007;104:176-180.
10. Prat A, Parera M, Peralta S, et al.: Nadir CA-125 concentration in the normal range as an independent prognostic factor for optimally treated advanced epithelial ovarian cancer. Ann Oncol 2008;19:327-331. (Pubitemid 351201715)
11. Baron AT, Maihle N: Nadir CA-125 concentration as a prognostic indicator in ovarian cancer. Nat Clin Pract Oncol 2005;2:288-289. (Pubitemid 40903169)
12. Bristow RE, Tomacruz RS, Armstrong DK, et al.: Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: A meta-analysis. J Clin Oncol 2002;20:1248-1259.